A phase IIa study of FP 025 for the treatment of asthma

Trial Profile

A phase IIa study of FP 025 for the treatment of asthma

Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs FP 025 (Primary)
  • Indications Asthma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Foresee Pharmaceuticals
  • Most Recent Events

    • 04 Dec 2017 According to a Foresee Pharmaceuticals media release, this Phase 2 proof-of-concept trial will be initiated in first half of 2018. This will further define a registration pathway and strategy.
    • 18 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top